title: Progelatinase B/matrix metalloproteinase-9 proenzyme as a marker of pleural inflammation.
abstract: Previous analyses of pleural effusions of different origin revealed high levels of matrix metalloproteinase-9 proenzyme (proMMP-9), predominantly in parainfectious exudates. To confirm the etiological association with inflammation and to explore time course of release of proMMP-9 under conditions of a local inflammatory reaction, the authors estimated proMMP-9 in pleural fluids of patients undergoing therapeutic talc pleurodesis (n = 20) and explorative thoracoscopy (n = 4), before, and at different time intervals after the intervention. The authors also compared proMMP-9 values with proinflammatory markers, such as interleukin-6 (IL-6), C-reactive protein (CRP), and leukocyte count. As revealed through scanning substrate electrophoresis, proMMP-9 levels increased within the first hours a!nd culminated 16 to 48 hours after intervention, amounting to 1.5- to 102 -fold of initial concentration (mean = 14.8 -fold). MMP-9 proenzyme values significantly correlated with the levels of proinflammatory cytokine IL-6 (r =.79, n = 47, p <.01) and with neutrophil counts (r =.75, n = 45, p <.01). In conclusion, the results present proMMP-9 as a novel early indicator of acute host-response in pleural space that complements traditional proinflammatory markers and might be useful in monitoring pleural inflammatory processes.
authors.affiliation: Institute of Biochemistry, Medical Faculty in Pilsen, Charles University, The Czech Republic. jaromir.kotyza@lfp.cuni.cz
authors.forename: Jaromír
authors.initials: J
authors.lastname: Kotyza
authors.forename: Milos
authors.initials: M
authors.lastname: Pesek
authors.forename: Petr
authors.initials: P
authors.lastname: Puzman
authors.forename: David
authors.initials: D
authors.lastname: Havel
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000032:analysis; D002097:C-Reactive Protein / Q000378:metabolism; D004792:Enzyme Precursors / Q000378:metabolism*; D005260:Female; D018093:Gelatinases / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000201:enzymology*; D015850:Interleukin-6 / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D007958:Leukocyte Count; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008666:Metalloendopeptidases / Q000378:metabolism*; D008875:Middle Aged; D010994:Pleura / Q000201:enzymology* / Q000473:pathology*; D010996:Pleural Effusion / Q000166:cytology; D018700:Pleurodesis / Q000009:adverse effects; D013627:Talc / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013906:Thoracoscopy / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004792:Enzyme Precursors; D015850:Interleukin-6; D013627:Talc; D002097:C-Reactive Protein; D007770:L-Lactate Dehydrogenase; D018093:Gelatinases; D008666:Metalloendopeptidases; C069860:progelatinase; D020780:Matrix Metalloproteinase 9